SBC Medical Group Holdings Incorporated · NASDAQ:SBC
SBC Medical — Q3 2026 Earnings Presentation
26 slides from SBC Medical's earnings presentation, Nov 13, 2026
Slide 1: 3Q 2026 Investor Presentation
About Us 3Q 2026 Investor Presentation November 2026
Slide 2: Disclaimer
About Us Disclaimer This presentation contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the beliefs of SBC Medical Group Holdings Incorporated (the "Company") regarding future events and performanc
Slide 3: Table of Contents
About Us Table of Contents I. 3Q 2026 Clinic Highlights P4 II. 3Q 2026 Performance Highlights P6 III. Business Strategies Update P9 IV. Capital & IR P15 Appendix. P17 3
Slide 4: 3Q 2026 Clinic Highlights
About Us Ⅰ. 3Q 2026 Clinic Highlights 4
Slide 5: 3Q 2026 Clinic Highlights
About 3Q 2026 Clinic Highlights ClinicUs • Same-clinic revenue⁵ grew 7% YoY, driven by growth in both customer visits and average spend Highlights per visit, alongside continued clinic network expansion Number of Locations1 Total Clinic Revenue1 2 3 4 Average Spend per Visit1 2 3 6 7 8 (as of Sep 30
Slide 6: 3Q 2026 Performance Highlights
About Us Ⅱ. 3Q 2026 Performance Highlights 6
Slide 7: 3Q 2026 Financial Performance Highlights
About 3Q 2026 Financial Performance Highlights Performance Us Total revenues Income from operations Adjusted EBITDA1 Basic EPS5 $59 MM $26 MM $28 MM $0.15 Highlights +35% YoY +66% YoY +66% YoY +25% YoY Unit 3Q26 2Q26 3Q25 QoQ YoY Total revenues MM US$ 59 +19% +35% 49 43 Income from operations MM US$
Slide 8: 3Q 2026 Performance Highlights
About 3Q 2026 Performance Highlights Performance Us • Total revenues +35% YoY and income from operations +66%; operating margin improved from 37% to 45%, driven mainly by growth in management services revenue Highlights (MM US$) 3Q26 2Q26 3Q25 Change & Contributing Factors - YoY (MM US$) QoQ YoY Tot
Slide 9: Business Strategies Update
About Us Ⅲ. Business Strategies Update 9
Slide 10: Roadmap for the Full-Scale Rollout of Our Longevity Business
About Business Roadmap for the Full-Scale Rollout of Our Longevity Business Us Strategies Update • Leveraging our extensive clinic network as a source of competitive advantage, we will build an end-to-end platform — from testing and diagnostics to personalized treatment and verification of outcomes
Slide 11: Development of DNA Methylation Testing — Measuring Biological Age
About Business Development of DNA Methylation Testing — Measuring Biological Age Us Strategies Update • We have begun in-house development of DNA methylation testing to estimate biological age, drawing on the research and technology base Waqoo Group has built in regenerative medicine Why DNA Methyla
Slide 12: Building Our Own Local LLM — Secure AI Strategy
About Business Building Our Own Local LLM — Secure AI Strategy to Utilize Medical Data Us Strategies Update • We are building our own local LLM foundation that protects medical data and enables AI features built on our proprietary data Why Local LLM Six AI Features Being Developed with Our Proprieta
Slide 13: Advancing Our Clinic Platform — Co-Development with Atomic Software
About Business Advancing Our Clinic Platform — Co-Development with Atomic Software Us Strategies Update • Capital & business alliance with Atomic Software, provider of Japan’s leading self-pay clinic platform “medicalforce,” to co-develop new features that boost clinics’ productivity and profitabili
Slide 14: Selected for Newsweek's World Medical Tourism Ranking 2027
About Business Selected for Newsweek’s World Medical Tourism Ranking 2027 Us Strategies Update • Shonan Beauty Clinic selected in two plastic surgery categories (top 75 in each)¹ • 3Q26 number of overseas customers’ visits² grew +86% YoY Survey Overview Our Results and Initiatives for Overseas Custo
Slide 15: IV. Capital & IR
IV. Capital & IR SBC Medical Group ticwines 15
Slide 16: Capital & IR — Improving Share Liquidity
About Capital & IR — Improving Share Liquidity Capital Us& IR • Average daily trading value¹ ² of SBC shares reached $1,026K in October, with share liquidity steadily improving • We will continue active investor engagement to further raise SBC’s recognition in the equity market Average daily trading
Slide 17: Appendix
Appendix. SBC Medical Group tio 17
Slide 18: 9M 2026 Performance Highlights
About 9M 2026 Performance Highlights Appendix. Us (MM US$) 9M26 9M25 Change & Contributing Factors - YoY (MM US$) YoY 151 +13% 134 Total revenues: +16.8 (FX impact: (9.9)) Total revenues 141 +5% 134 (Figures below exclude FX impact) SBC core segment 28 (21)% 36 • Franchising revenue: (5.5) • Franchi
Slide 19: Consolidated Income Statement
About Consolidated Income Statement Appendix. Us (MM US$) 3Q26 2Q26 3Q25 9M26 9M25 QoQ YoY YoY Total revenues 59 +19% +35% 49 43 151 +13% 134 SBC core segment 53 +19% +22% 45 43 141 +5% 134 • Franchising revenue 10 +1% (4)% 10 10 28 (21)% 36 • Procurement revenue 14 +6% +6% 13 13 40 (8)% 43 • Manage
Slide 20: Consolidated Balance Sheet
About Consolidated Balance Sheet Appendix. Us Sep. Dec. Sep. Dec. (MM US$) (MM US$) 2026 Change 2025 2026 Change 2025 TOTAL ASSETS 425 +44 380 TOTAL LIABILITIES 121 +4 117 Total current assets 274 +43 231 Total current liabilities 75 +14 61 • Cash and cash equivalents 198 +35 164 • Accounts payable
Slide 21: Consolidated Statement of Cash Flows
About Consolidated Statement of Cash Flows Appendix. Us (MM US$) 9M26 9M25 YoY Net cash provided by (used in) operating activities 50 +77 (27) Net cash provided by (used in) investing activities (5) (8) 3 Net cash provided by (used in) financing activities (9) (27) 18 Effect of changes in foreign cu
Slide 22: Strong Financial Foundation for Growth
About Strong Financial Foundation for Growth Appendix. Us • Strong financial base ($154M net cash, 68% equity ratio) to support continued growth investments Cash and Cash Equivalents Interest-Bearing Liabilities2 Net Cash4 $198 MM $44 MM $154 MM Net cash per share 5 : $1.51 Capital Ratio1 Adjusted D
Slide 23: Non-GAAP Financial Measures
About Non-GAAP Financial Measures Appendix. Us This presentation references certain non-GAAP financial measures. Reconciliations of such measures to the most directly comparable GAAP measures are shown below. Reconciliation Table on Non-GAAP Financials (MM US$) 3Q26 2Q26 3Q25 (A) Total revenues 59 4
Slide 24: Non-GAAP Financial Measures
About Non-GAAP Financial Measures Appendix. Us This presentation references certain non-GAAP financial measures. Reconciliations of such measures to the most directly comparable GAAP measures are shown below. Reconciliation Table on Non-GAAP Financials (MM US$) Sep. 2026 Dec. 2025 (A) Bank and other
Slide 25: Investment Highlights
About Investment Highlights Appendix. Us A highly profitable Medical Services Organization (MSO) model with 7.06MM 1 Japan’s #11 aesthetic healthcare platform annual visits, a 73% repeat rate², and a 47% adjusted EBITDA margin² ³ Longevity: we already own the hardest piece to Combining diagnostics a
Slide 26: Thank you
About Us Thank you Contact: ir@sbc-holdings.com IR Site LinkedIn
SBC Medical Group Holdings — Q3 2026 Earnings Presentation on 6ix